Table 2.
Clinical outcomes and their probabilities
| Clinical outcome | No. of subjects (%) |
P | |||
|---|---|---|---|---|---|
| DDAT approacha |
Standard approachb (n = 1,095) | ||||
| –EAT (n = 33) | +EAT (n = 52) | Total (n = 85) | |||
| Overall therapeutic success | 16 (48.48) | 15 (28.85) | 31 (36.47) | 371 (33.88) | 0.62 |
| Therapeutic failure due toc: | 17 (51.51) | 37 (71.15) | 54 (63.53) | 724 (66.12) | 0.62 |
| Death | 11 (21.15) | 11 (12.94) | 99 (9.04) | 0.17 | |
| Breakthrough IFI | 1 (1.92) | 1 (1.18) | 53 (4.84) | 0.17 | |
| Premature discontinuation | 7 (13.46) | 7 (8.23) | 218 (19.91) | 0.007 | |
| Persistent fever | 17 (51.51) | 18 (34.61) | 35 (41.18) | 354 (32.33) | 0.02 |
a
The DDAT approach was the approach recommended by the SAEI (12). −EAT, Patients did not receive EAT; +EAT, patients received EAT.
b
The standard approach was the EAT approach recommended by the IDSA (4). All patients received EAT.
c
IFI, invasive fungal infection. Premature discontinuation involves the lack of efficacy and toxicity. Persistent fever was determined as the number of patients who failed therapy because of a reason other than persistent fever.